UBS Group’s Tema Oncology ETF CANC Stock Holding History

UBS Group’s Portfolio CANC Stock Details CANC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-605	Closed	-$17.4K	–	10547
2025 Q3	$17.4K	Buy	+605	New	+$16.1K	﹤0.01%	8250
2025 Q2	–	Sell	-223	Closed	-$5.37K	–	10293
2025 Q1	$5.37K	Buy	+223	New	+$5.61K	﹤0.01%	9005

Other funds holding CANC

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Willow Financial Rogers, Arkansas $98.7M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TCM

TD Capital Management Memphis, Tennessee $1.22B AUM 13.44% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group's CANC Position: Q4 2025 in Review

UBS Group sold out of Tema Oncology ETF (CANC) in Q4 2025, closing a stake of 605 shares — an estimated $17.4K sold.

UBS Group first reported a position in CANC in Q1 2025 and held it in 2 quarters. The position peaked at $17.4K in Q3 2025. 6 funds tracked by Wall St. Rank hold CANC as of Q4 2025.

UBS Group reported no remaining Tema Oncology ETF position as of Q4 2025 after selling out during the quarter.
UBS Group sold 605 Tema Oncology ETF shares in Q4 2025, an estimated $17.4K.
UBS Group first reported a position in Tema Oncology ETF in Q1 2025 and held it in 2 quarters.
UBS Group's Tema Oncology ETF position peaked at $17.4K in Q3 2025.
6 funds tracked by Wall St. Rank held Tema Oncology ETF as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.